Rilzabrutinib Approved For Immune Thrombocytopenia Treatment
Rilzabrutinib has been authorized for the treatment of adults with immune thrombocytopenia who have not responded to prior treatments. The approval was issued by the Medicines and Healthcare products Regulatory Agency.
Topics
Developing
- 883d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 883d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 883d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 883d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
Bluesky Social
“Rilzabrutinib authorised to treat adults with immune thrombocytopenia when prior treatments have bee. Rilzabrutinib authorised to treat adults with immune thrombocytopenia when prior treatments have been insufficient”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade